Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021

バイオマーカーの世界市場予測(~2021年):安全性マーカー、予測マーカー、代替マーカー、薬力学マーカー、予後マーカー

◆タイトル:Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021
◆商品コード:MAM-BT-2120
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年2月17日
◆ページ数:160
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオ技術
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、バイオマーカーの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、製品別分析、種類別分析、疾患別分析、用途別分析、バイオマーカーの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global biomarkers market is estimated to reach USD 53.34 billion by 2021 from USD 27.95 billion in 2016, at a CAGR of 13.8% from 2016 to 2021.Increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, increasing number of CROs and low cost of clinical trials in developing countries, the high prevalence of cancer, and new initiatives for biomarker research are the major factors driving the growth of the global biomarkers market. In recent years, the Asian biomarkers market has witnessed significant growth due to the increasing use of biomarkers for diagnostic purposes, increasing incidence of chronic diseases, and increasing outsourcing of pharmaceutical R&D activities to outsourcing partners in Asia.

In this report, the global biomarkers market is segmented on the basis of product, type, application, disease indication, and region. On the basis of product, the biomarkers market is segmented into consumables, services, and software. The consumables segment is estimated to account for the largest share of the global biomarkers market in 2016. The large share can primarily be attributed to the lower price of consumables than that of screening and automation instruments.

On the basis of type, the biomarkers market is segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers. The efficacy biomarkers segment if further segmented into predictive biomarkers, surrogate biomarkers, pharmacodynamic biomarkers, and prognostic biomarkers. The safety biomarkers segment is estimated to account for the largest share in 2016. This is due to their widespread applications in drug discovery and development.

On the basis of application, the biomarkers market is categorized into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications (DNA fingerprinting, ecotoxicology, and forensics). The diagnostics segment is estimated to account for the largest share of the market in 2016. Factors such as increasing prevalence of cancer, technologically developed biomarker products, individualized treatments for cancer, and the need for early-stage cancer diagnosis are driving the growth of this segment in the biomarkers market.

On the basis of disease indication, the biomarkers market is categorized into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others (renal disorders, urinal diseases, diabetes, and tuberculosis). The cancer segment is estimated to account for the largest share of the biomarkers market in 2016. This is primarily attributed to the increasing prevalence of cancer. The use of cancer biomarkers provides great opportunities for improving the management of cancer patients by enhancing detection and efficacy of treatment.

New product launches was the dominant strategy adopted by key industry participants to increase their market share and cater to unmet needs.

Research Coverage:
From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats), winning imperatives, and burning issues. The report also offers market sizes and data on the growth of various segments in the industry. It focuses on emerging and high-growth segments, high-growth regions, and initiatives of governments. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to buy this report:
From an insight perspective, this research report focuses on various levels of analysis—industry analysis (industry trends) and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments of the biomarkers market; high-growth regions; and market drivers, restraints, and opportunities.

The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on products offered by the top players in the biomarkers market
• Product Development/Innovation: Detailed insights on the upcoming technologies, research & development activities, and new product launches in the biomarkers market
• Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for biomarker products across various regions
• Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the biomarkers market
• Competitive Assessment: In-depth assessment of market ranking, strategies, products, and manufacturing capabilities of the leading players in the biomarkers market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 MARKET SCOPE 13
1.3.1 MARKETS COVERED 14
1.3.2 YEARS CONSIDERED IN THE REPORT 15
1.4 CURRENCY 15
1.5 LIMITATIONS 15
1.6 STAKEHOLDERS 16

2 RESEARCH METHODOLOGY 17
2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.2.1 KEY DATA FROM SECONDARY SOURCES 22
2.2.2 KEY DATA FROM PRIMARY SOURCES 22
2.3 MARKET RANK ESTIMATION 23
2.4 KEY INDUSTRY INSIGHTS 23
2.5 ASSUMPTIONS FOR THE STUDY 24

3 EXECUTIVE SUMMARY 25

4 PREMIUM INSIGHTS 29
4.1 BIOMARKERS: MARKET OVERVIEW 29
4.2 GEOGRAPHIC ANALYSIS: BIOMARKERS MARKET, BY PRODUCT (2016) 30
4.3 BIOMARKERS MARKET, BY TYPE, 2016 VS. 2021 31
4.4 BIOMARKERS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 31
4.5 BIOMARKERS MARKET, BY DISEASE INDICATION, 2016 VS. 2021 32
4.6 BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 32
4.7 LIFE CYCLE ANALYSIS, BY REGION, 2016 33

5 MARKET OVERVIEW 34
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Increasing diagnostic applications of biomarkers 36
5.2.1.1.1 Personalized medicine 36
5.2.1.1.2 Companion diagnostics 36

5.2.1.2 Increasing R&D funding for pharma and biotech companies 37
5.2.1.3 Increasing number of CROs and low cost of clinical trials in developing countries 38
5.2.1.4 High prevalence of cancer 38
5.2.1.5 New initiatives for biomarker research 40
5.2.2 RESTRAINTS 40
5.2.2.1 High capital investments and low cost-benefit ratio 40
5.2.2.2 Poorly suited regulatory and reimbursement systems 41
5.2.2.3 Technical issues related to sample collection and storage 41
5.2.3 OPPORTUNITIES 42
5.2.3.1 Emerging economies 42
5.2.4 CHALLENGES 42
5.2.4.1 Proving the clinical validity in biomarker-based tests 42

6 BIOMARKERS MARKET, BY PRODUCT 43
6.1 INTRODUCTION 44
6.2 CONSUMABLES 45
6.3 SERVICES 46
6.4 SOFTWARE 48

7 BIOMARKERS MARKET, BY TYPE 50
7.1 INTRODUCTION 51
7.2 SAFETY BIOMARKERS 52
7.3 EFFICACY BIOMARKERS 54
7.3.1 PREDICTIVE BIOMARKERS 57
7.3.2 SURROGATE BIOMARKERS 58
7.3.3 PHARMACODYNAMIC BIOMARKERS 59
7.3.4 PROGNOSTIC BIOMARKERS 60
7.4 VALIDATION BIOMARKERS 61

8 BIOMARKERS MARKET, BY APPLICATION 63
8.1 INTRODUCTION 64
8.2 DIAGNOSTICS 65
8.3 DRUG DISCOVERY AND DEVELOPMENT 67
8.4 PERSONALIZED MEDICINE 69
8.5 DISEASE RISK ASSESSMENT 71
8.6 OTHER APPLICATIONS 73

9 BIOMARKERS MARKET, BY DISEASE INDICATION 76
9.1 INTRODUCTION 77
9.2 CANCER 78
9.3 CARDIOVASCULAR DISORDERS 81
9.4 NEUROLOGICAL DISORDERS 83
9.5 IMMUNOLOGICAL DISORDERS 84
9.6 OTHER DISEASES 86

10 BIOMARKERS MARKET, BY REGION 89
10.1 INTRODUCTION 90
10.2 NORTH AMERICA 92
10.2.1 U.S. 95
10.2.2 CANADA 98
10.3 EUROPE 101
10.4 ASIA 104
10.4.1 CHINA 108
10.4.2 JAPAN 111
10.4.3 REST OF ASIA 113
10.5 REST OF THE WORLD (ROW) 115

11 COMPETITIVE LANDSCAPE 118
11.1 OVERVIEW 118
11.2 COMPETITIVE SITUATION AND TRENDS 119
11.2.1 PRODUCT LAUNCHES 120
11.2.2 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS 121
11.2.3 ACQUISITIONS 122
11.2.4 OTHER DEVELOPMENTS 122
11.3 LEADING PLAYERS IN THE BIOMARKERS MARKET 123

12 COMPANY PROFILES 124
(Overview, Products and Services, Financials, Strategy & Development)*
12.1 QIAGEN N.V. 125
12.2 PERKINELMER, INC. 128
12.3 MERCK MILLIPORE 131
12.4 BIO-RAD LABORATORIES, INC. 134
12.5 ENZO BIOCHEM, INC. 136
12.6 EKF DIAGNOSTICS HOLDINGS, INC. 139
12.7 MESO SCALE DIAGNOSTICS, LLC. 141
12.8 BIOSIMS TECHNOLOGIES SAS 142
12.9 CISBIO BIOASSAYS 143
12.10 SIGNOSIS, INC. 145
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13 APPENDIX 146
13.1 INSIGHTS OF INDUSTRY EXPERTS 146
13.2 DISCUSSION GUIDE 147
13.3 OTHER DEVELOPMENTS 149
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 151
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 153
13.6 AVAILABLE CUSTOMIZATIONS 155
13.7 RELATED REPORTS 156
13.8 AUTHOR DETAILS 157

LIST OF TABLES

TABLE 1 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER 39
TABLE 2 BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION) 44
TABLE 3 BIOMARKER CONSUMABLES MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 45
TABLE 4 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION) 45
TABLE 5 ASIA: BIOMARKER CONSUMABLES MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 46
TABLE 6 BIOMARKER SERVICES MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 47
TABLE 7 NORTH AMERICA: BIOMARKER SERVICES MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 47
TABLE 8 ASIA: BIOMARKER SERVICES MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 48
TABLE 9 BIOMARKER SOFTWARE MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 48
TABLE 10 NORTH AMERICA: BIOMARKER SOFTWARE MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 49
TABLE 11 ASIA: BIOMARKER SOFTWARE MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 49
TABLE 12 BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 52
TABLE 13 SAFETY BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 53
TABLE 14 NORTH AMERICA: SAFETY BIOMARKERS MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 53
TABLE 15 ASIA: SAFETY BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION) 54
TABLE 16 EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 55
TABLE 17 EFFICACY BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 55
TABLE 18 NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 56
TABLE 19 ASIA: EFFICACY BIOMARKERS MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 56
TABLE 20 PREDICTIVE BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 57
TABLE 21 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 57
TABLE 22 SURROGATE BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 58
TABLE 23 NORTH AMERICA: SURROGATE BIOMARKERS MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 58
TABLE 24 PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY REGION,
2014–2021 (USD BILLION) 59
TABLE 25 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION) 59
TABLE 26 PROGNOSTIC BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 60
TABLE 27 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 60
TABLE 28 VALIDATION BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 61
TABLE 29 NORTH AMERICA: VALIDATION BIOMARKERS MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 61
TABLE 30 ASIA: VALIDATION BIOMARKERS MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 62
TABLE 31 BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION) 65
TABLE 32 BIOMARKERS MARKET SIZE FOR DIAGNOSTICS DEVELOPMENT, BY REGION, 2014–2021 (USD BILLION) 66
TABLE 33 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR DIAGNOSTICS DEVELOPMENT, BY COUNTRY, 2014–2021 (USD BILLION) 66
TABLE 34 ASIA: BIOMARKERS MARKET SIZE FOR DIAGNOSTICS DEVELOPMENT,
BY COUNTRY, 2014–2021 (USD BILLION) 67
TABLE 35 BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT,
BY REGION, 2014–2021 (USD BILLION) 68
TABLE 36 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2014–2021 (USD BILLION) 68
TABLE 37 ASIA: BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT,
BY COUNTRY, 2014–2021 (USD BILLION) 69
TABLE 38 BIOMARKERS MARKET SIZE FOR PERSONALIZED MEDICINE, BY REGION,
2014–2021 (USD BILLION) 70
TABLE 39 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2014–2021 (USD BILLION) 70
TABLE 40 ASIA: BIOMARKERS MARKET SIZE FOR PERSONALIZED MEDICINE, BY COUNTRY, 2014–2021 (USD BILLION) 71
TABLE 41 BIOMARKERS MARKET SIZE FOR DISEASE RISK ASSESSMENT, BY REGION,
2014–2021 (USD BILLION) 72
TABLE 42 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2014–2021 (USD BILLION) 72
TABLE 43 ASIA: BIOMARKERS MARKET SIZE FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2014–2021 (USD BILLION) 73
TABLE 44 BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION,
2014–2021 (USD BILLION) 74
TABLE 45 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS,
BY COUNTRY, 2014–2021 (USD BILLION) 74
TABLE 46 ASIA: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY COUNTRY, 2014–2021 (USD MILLION) 75
TABLE 47 BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION) 78
TABLE 48 KEY CANCER BIOMARKERS IN CLINICAL USE 79
TABLE 49 BIOMARKERS MARKET SIZE FOR CANCER, BY REGION, 2014–2021 (USD BILLION) 79
TABLE 50 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CANCER, BY COUNTRY,
2014–2021 (USD BILLION) 80
TABLE 51 ASIA: BIOMARKERS MARKET SIZE FOR CANCER, BY COUNTRY,
2014–2021 (USD BILLION) 80
TABLE 52 BIOMARKERS FOR CARDIOVASCULAR DISORDER 81
TABLE 53 BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2014–2021 (USD BILLION) 81
TABLE 54 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2014–2021 (USD BILLION) 82
TABLE 55 ASIA: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS,
BY REGION/COUNTRY, 2014–2021 (USD BILLION) 82
TABLE 56 BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION,
2014–2021 (USD BILLION) 83
TABLE 57 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2014–2021 (USD BILLION) 83
TABLE 58 ASIA: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS,
BY REGION/COUNTRY, 2014–2021 (USD BILLION) 84
TABLE 59 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS 84
TABLE 60 BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2014–2021 (USD BILLION) 85
TABLE 61 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2014–2021 (USD BILLION) 85
TABLE 62 ASIA: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS,
BY REGION/COUNTRY, 2014–2021 (USD BILLION) 86
TABLE 63 BIOMARKERS FOR RENAL DISORDERS 86
TABLE 64 BIOMARKERS MARKET SIZE FOR OTHER DISEASES, BY REGION,
2014–2021 (USD BILLION) 87
TABLE 65 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER DISEASES,
BY COUNTRY, 2014–2021 (USD BILLION) 87
TABLE 66 ASIA: BIOMARKERS MARKET SIZE FOR OTHER DISEASES, BY COUNTRY,
2014–2021 (USD BILLION) 88
TABLE 67 BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION) 91
TABLE 68 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY COUNTRY,
2014–2021 (USD BILLION) 93
TABLE 69 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 93
TABLE 70 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 93
TABLE 71 NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 94
TABLE 72 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 94
TABLE 73 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD BILLION) 95
TABLE 74 U.S.: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION) 96
TABLE 75 U.S.: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 96
TABLE 76 U.S.: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 97
TABLE 77 U.S.: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION) 97
TABLE 78 U.S.: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD BILLION) 98
TABLE 79 CANADA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION) 98
TABLE 80 CANADA: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 99
TABLE 81 CANADA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 99
TABLE 82 CANADA: BIOMARKERS MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 100
TABLE 83 CANADA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD BILLION) 100
TABLE 84 EUROPE: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION) 101
TABLE 85 EUROPE: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 102
TABLE 86 EUROPE: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE,
2014–2021 (USD BILLION) 102
TABLE 87 EUROPE: BIOMARKERS MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 103
TABLE 88 EUROPE: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD BILLION) 103
TABLE 89 ASIA: BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION) 106
TABLE 90 ASIA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION) 106
TABLE 91 ASIA: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 106
TABLE 92 ASIA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 107
TABLE 93 ASIA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION) 107
TABLE 94 ASIA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD BILLION) 108
TABLE 95 CHINA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION) 109
TABLE 96 CHINA: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 109
TABLE 97 CHINA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION) 110
TABLE 98 CHINA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD BILLION) 110
TABLE 99 JAPAN: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION) 111
TABLE 100 JAPAN: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 111
TABLE 101 JAPAN: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION) 112
TABLE 102 JAPAN: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD BILLION) 112
TABLE 103 REST OF ASIA: BIOMARKERS MARKET SIZE, BY PRODUCT,
2014–2021 (USD BILLION) 113
TABLE 104 REST OF ASIA: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 113
TABLE 105 REST OF ASIA: BIOMARKERS MARKET SIZE, BY APPLICATION,
2014–2021 (USD BILLION) 114
TABLE 106 REST OF ASIA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD BILLION) 114
TABLE 107 ROW: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION) 115
TABLE 108 ROW: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 115
TABLE 109 ROW: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION) 116
TABLE 110 ROW: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION) 116
TABLE 111 ROW: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2014–2021 (USD BILLION) 117
TABLE 112 BATTLE FOR MARKET SHARE: PRODUCT LAUNCH WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS IN BIOMARKERS MARKET BETWEEN
2014 AND 2016 119
TABLE 113 PRODUCT LAUNCHES, 2014–2016 120
TABLE 114 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS, 2014–2016 121
TABLE 115 ACQUISITIONS, 2014–2016 122
TABLE 116 OTHER DEVELOPMENTS, 2014–2016 122
TABLE 117 RANK OF COMPANIES IN THE BIOMARKERS MARKET, 2016 123


LIST OF FIGURES

FIGURE 1 BIOMARKERS MARKET SEGMENTATION 14
FIGURE 2 RESEARCH DESIGN 17
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 19
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 19
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 20
FIGURE 6 DATA TRIANGULATION METHODOLOGY 21
FIGURE 7 BIOMARKERS MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD BILLION) 25
FIGURE 8 BIOMARKERS MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD BILLION) 26
FIGURE 9 BIOMARKERS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD BILLION) 26
FIGURE 10 BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2016 VS. 2021
(USD BILLION) 27
FIGURE 11 BIOMARKERS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD BILLION) 28
FIGURE 12 BIOMARKERS MARKET TO REGISTER A HIGH, DOUBLE-DIGIT GROWTH RATE DURING THE FORECAST PERIOD 29
FIGURE 13 CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET
SHARE IN 2016 30
FIGURE 14 SAFETY BIOMARKERS WILL CONTINUE TO DOMINATE THE BIOMARKERS
MARKET IN 2021 31
FIGURE 15 DIAGNOSTICS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2016 31
FIGURE 16 CANCER SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2016 32
FIGURE 17 ASIA TO ACCOUNT FOR THE HIGHEST CAGR DURING THE FORECAST PERIOD 32
FIGURE 18 ASIAN MARKET SHOWS LUCRATIVE GROWTH OPPORTUNITIES 33
FIGURE 19 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 35
FIGURE 20 INCREASING R&D INVESTMENTS BOOSTING GROWTH IN
THE BIOMARKERS MARKET 37
FIGURE 21 INCREASING NUMBER OF NEW CANCER CASES WORLDWIDE
(2012 VS. 2015 VS. 2020) 39
FIGURE 22 CONSUMABLES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF
THE BIOMARKERS MARKET IN 2016 44
FIGURE 23 SAFETY BIOMARKERS SEGMENT TO DOMINATE THE MARKET DURING
THE FORECAST PERIOD 51
FIGURE 24 DIAGNOSTICS APPLICATION SEGMENT TO ACCOUNT FOR THE LARGEST SHARE
OF THE BIOMARKERS MARKET IN 2016 64
FIGURE 25 CANCER TO FORM THE LARGEST SEGMENT IN THE BIOMARKERS MARKET IN 2016 77
FIGURE 26 BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT 90
FIGURE 27 ASIA: AN ATTRACTIVE DESTINATION FOR ALL APPLICATION CATEGORIES 91
FIGURE 28 NORTH AMERICA: MARKET SNAPSHOT 92
FIGURE 29 ASIA: MARKET SNAPSHOT 105
FIGURE 30 PRODUCT LAUNCH, THE MOST ADOPTED GROWTH STRATEGY FROM
2014 TO 2016 118
FIGURE 31 GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS (2015) 124
FIGURE 32 COMPANY SNAPSHOT: QIAGEN N.V. (2015) 125
FIGURE 33 COMPANY SNAPSHOT: PERKINELMER, INC. (2015) 128
FIGURE 34 COMPANY SNAPSHOT: MERCK MILLIPORE (2015) 131
FIGURE 35 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2015) 134
FIGURE 36 COMPANY SNAPSHOT: ENZO BIOCHEM, INC. (2016) 136
FIGURE 37 COMPANY SNAPSHOT: EKF DIAGNOSTICS HOLDINGS, INC. (2015) 139


【レポートのキーワード】

バイオマーカー、バイオマーカー消耗品、バイオマーカーサービス、癌バイオマーカー、心血管系疾患バイオマーカー、診断、検査、医療機器、安全性マーカー、予測マーカー、代替マーカー、薬力学マーカー、予後マーカー

★調査レポート[バイオマーカーの世界市場予測(~2021年):安全性マーカー、予測マーカー、代替マーカー、薬力学マーカー、予後マーカー] ( Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021 / MAM-BT-2120) 販売に関する免責事項
[バイオマーカーの世界市場予測(~2021年):安全性マーカー、予測マーカー、代替マーカー、薬力学マーカー、予後マーカー] ( Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021 / MAM-BT-2120) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆